Pain Management: World Prescription Drug Markets

1.1 Scope and Objectives of Report
1.2 Methodology
1.2.1 Forecasting
1.3 Market Summary
1.3.1 Market Analysis
1.3.2 Market Trends and Opportunities

2 Pain Management Overview

2.1 Pain Definitions
2.1.1 Nociceptive Versus Neuropathic Pain
2.1.2 Acute Versus Chronic Pain
2.2 Major Pain Indications
2.2.1 Postoperative Pain
2.2.2 Visceral Pain
2.2.3 Labor Pain
2.2.4 Migraine
2.2.5 Back Pain
2.2.6 Cancer-related Pain
2.2.7 HIV/AIDS-associated Pain
2.2.8 Arthritic Pain
2.2.9 Neuropathies
2.3 Epidemiology
2.3.1 Global Pain Patient Populations
2.3.2 Postoperative Pain
2.3.3 Migraine
2.3.4 Back Pain
2.3.5 Cancer-related Pain
2.3.6 HIV/AIDS-associated Pain
2.3.7 Osteoarthritis Pain
2.3.8 Rheumatoid Arthritis Pain
2.3.9 Diabetic Neuropathy

3 Prescription Pain Treatments on the Market

3.1 Overview of Pain Treatment Options
3.1.1 Major Prescription Drug Classes
3.1.2 WHO Analgesic Ladder
3.1.3 Over-The-Counter Drugs
3.2 Traditional NSAIDs
3.2.1 NSAID Classes
3.2.2 Mechanism of Action
3.2.3 Treatment Indications
3.2.4 Adverse Events
3.2.5 Voltaren/Cataflam (diclofenac)
3.2.6 Arthrotec (diclofenac and misoprostol)
3.2.7 Relafen (nabumetone)
3.2.8 Daypro (oxaprozin)
3.2.9 Feldene (piroxicam)
3.2.10 Loxonin (loxoprofen)
3.3 COX-2 Inhibitors
3.3.1 Celebrex (celecoxib)
3.3.2 Vioxx (rofecoxib)
3.3.3 Dynastat (parecoxib)
3.4 Opioids
3.4.1 Opioid Treatment Strategies
3.4.2 Adverse Events
3.4.3 Opioid Tolerance and Dependence
3.4.4 OxyContin (oxycodone)
3.4.5 Duragesic (fentanyl)
3.4.6 Ultram/Ultracet (tramadol)
3.4.7 Avinza (modified-release morphine)
3.4.8 MS Contin
3.4.9 Stadol NS (butorphanol tartrate)
3.4.10 Opioid Combination Therapies
3.5 Migraine Drugs
3.5.1 Preventative Treatments
3.5.2 Abortive Treatments
3.6 Rheumatoid Arthritis Drugs
3.6.1 Disease-Modifying Antirheumatic Drugs
3.6.2 Biologic Response Modifiers

4 Pain Treatments in Development

4.1 Overview of Unmet Needs in Pain Management
4.1.1 NSAID Adverse Events
4.1.2 Opioid Addiction and Breakthrough Pain
4.1.3 Neuropathic Pain
4.2 NSAIDs and COX-2 Inhibitors
4.2.1 Bextra (valdecoxib)
4.2.2 Arcoxia (etoricoxib)
4.2.3 Prexige (lumiracoxib/COX-189)
4.2.4 Licofelone (ML3000)
4.2.5 Ketoprofen (transdermal)
4.2.6 NO-naproxen (HCT-3012/AZD3582)
4.3 Opioids
4.3.1 Chronogesic (sufentanil)
4.3.2 DepoMorphine (sustained-release morphine injection)
4.3.3 AERx PMS (aerosolized morphine)
4.3.4 Moraxen (controlled-release morphine suppository)
4.3.5 Oxycodone + Ibuprofen
4.3.6 Oxymorphone ER/IR
4.3.7 E-TRANS fentanyl
4.3.8 MorphiDex (morphine + dextromethorphan)
4.3.9 ADL 2-1294 (loperamide)
4.3.10 ADL 10-0101
4.3.11 DPI-3290/ORG-41793
4.3.12 HydrocoDex/OxycoDex/PercoDex
4.3.13 Intranasal Morphine
4.3.14 M6G (CEE 04-410/morphine-6-glucuronide)
4.3.15 MorViva/OxyTrex/PTI-601/PTI-701
4.3.16 Dirame
4.4 Neuropathic Pain Therapies
4.4.1 Neurontin (gabapentin)
4.4.2 Pregabalin
4.4.3 Prialt (ziconotide)
4.4.4 Memantine
4.4.5 ABT-594
4.4.6 CNS-5161
4.4.7 CT-3 (cannabinoid)
4.4.8 Devacade
4.4.9 NP-1 (amitriptyline + ketamine)
4.4.10 Prosaptide TX14(A)
4.4.11 Topamax (topiramate)

5 World Market Analysis of Pain Management Drugs

5.1 Total Global Market Sizes and Projections, 2000-2006
5.2 Historic Market Sizes, 2000-2001
5.2.1 By Drug Class
5.2.2 By Geographic Region
5.3 Market Sizes and Projections by Drug Class, 2000-2006
5.3.1 NSAIDs
5.3.2 COX-2 Inhibitors
5.3.3 Opioids
5.3.4 Other Pain Drug Therapies
5.4 Market Sizes and Projections by Leading Drugs, 2002-2006
5.4.1 Market Forecasts of Current Pain Treatment Drugs
5.4.2 Market Forecasts of Drugs in Development
5.5 Historic Market Sizes by Competitor, 2000-2001

6 Pain Management Market Trends and Opportunities

6.1 Market Trends
6.1.1 Patent Expiries
6.1.2 Cost Constraints in Europe, Japan, and U.S.
6.1.3 Opioid Abuse
6.1.4 Off-Label Drug Use
6.2 Market Growth Drivers
6.2.1 Growing Patient Base
6.2.2 Direct-to-Consumer Marketing
6.2.3 Novel Drug Formulations
6.2.4 New Indications
6.3 Market Opportunities
6.3.1 Brand Differentiation
6.3.2 Technology Differentiation
6.3.3 Indication Differentiation

7 Company Briefs

7.1 Novartis International AG
7.2 Pharmacia Corp.
7.3 GlaxoSmithKline
7.4 Pfizer Inc.
7.5 Merck & Co.
7.6 Purdue Pharma
7.7 Johnson & Johnson
7.8 Elan Corp., plc
7.9 Forest Laboratories
7.10 SkyePharma
7.11 Durect Corp.
7.12 Aradigm Corp.
7.13 CeNeS Pharmaceuticals plc
7.14 Pain Therapeutics, Inc.
7.15 Endo Pharmaceuticals

8 References

List of Tables

• Table 2-1 U.S. Chronic Pain Prevalence Statistics 2002-2006
• Table 2-2 Patient Populations With Acute and Chronic Pain by Geographic Market 2002
• Table 2-3 Patient Populations With Postoperative Pain by Geographic Market 2002
• Table 2-4 Patient Populations With Migraine by Geographic Market 2002
• Table 2-5 Patient Populations With Back Pain by Geographic Market 2002
• Table 2-6 Patient Populations With Cancer-related Pain by Geographic Market 2002
• Table 2-7 Patient Populations With HIV/AIDS-associated Pain by Geographic Market 2002
• Table 2-8 Patient Populations With Osteoarthritis Pain by Geographic Market 2002
• Table 2-9 Patient Populations With Rheumatoid Arthritis Pain by Geographic Market 2002
• Table 2-10 Patient Populations With Diabetic Neuropathy by Geographic Market 2002
• Table 3-1 NSAID Classes and Formulations
• Table 3-2 Voltaren/Cataflam (diclofenac) Drug Profile
• Table 3-3 Arthrotec (diclofenac/misoprostol) Drug Profile
• Table 3-4 Relafen (nabumetone) Drug Profile
• Table 3-5 Celebrex (celecoxib) Drug Profile
• Table 3-6 Vioxx (rofecoxib) Drug Profile
• Table 3-7 OxyContin (oxycodone) Drug Profile
• Table 3-8 Duragesic (fentanyl) Drug Profile
• Table 3-9 Ultram/Ultracet (tramadol) Drug Profile
• Table 3-10 Avinza (modified-release morphine) Drug Profile
• Table 4-1 NSAID and COX-2 Inhibitor Drug Pipeline for Pain Management 2002
• Table 4-2 Opioid Drug Pipeline for Pain Management 2002
• Table 4-3 Neuropathic Pain Drug Pipeline for Pain Management 2002
• Table 5-1 Total World Pain Management Drug Market 2000-2006
• Table 5-2 World Pain Management Drug Market by Drug Class 2000-2001
• Table 5-3 World Pain Management Drug Market by Geographic Region 2000-2001
• Table 5-4 World Pain Management NSAID Market 2002-2006
• Table 5-5 World Pain Management NSAID Market by Product 2000-2001
• Table 5-6 World Pain Management NSAID Market by Geographic Region 2000-2001
• Table 5-7 World Pain Management COX-2 Inhibitor Market 2002-2006
• Table 5-8 World Pain Management COX-2 Inhibitor Market by Product 2000-2001
• Table 5-9 World Pain Management COX-2 Inhibitor Market by Geographic Region 2000-2001
• Table 5-10 World Pain Management Opioid Market 2002-2006
• Table 5-11 World Pain Management Opioid Market by Product 2000-2001
• Table 5-12 World Pain Management Opioid Market by Geographic Region 2000-2001
• Table 5-13 World Pain Management Market for Other Drug Therapies 2002-2006
• Table 5-14 World Pain Management Market for Other Drug Therapies by Geographic Region 2000-2001
• Table 5-15 World Pain Management Drug Market Projections by Current Product 2002-2006
• Table 5-16 World Pain Management Drug Market Projections by Product in Development/Approved Not Indicated 2002-2006
• Table 5-17 Leading Companies by World Pain Management Drug Revenues 2000-2001
• Table 5-18 Leading Companies by U.S. Pain Management Drug Revenues 2000-2001